News Column

Data on Radiochemistry Detailed by Researchers at Belgian Nuclear Research Center (Separation of Nb-90 from zirconium target for application in...

July 2, 2014

Data on Radiochemistry Detailed by Researchers at Belgian Nuclear Research Center (Separation of Nb-90 from zirconium target for application in immuno-PET)

By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Radiochemistry are discussed in a new report. According to news reporting originating in Mol, Belgium, by NewsRx journalists, research stated, "Fast progressing immuno- PET asks to explore new radionuclides. One of the promising candidates is Nb-90."

The news reporters obtained a quote from the research from Belgian Nuclear Research Center, "It has a half-life of 14.6 h that allows visualizing and quantifying biological processes with medium and slow kinetics, such as tumor accumulation of antibodies and antibodies fragments or drug delivery systems and nanoparticles. Nb-90 exhibits a positron branching of 53% and an average kinetic energy of emitted positrons of.. mean = 0.35MeV. Currently, radionuclide production routes and Nb V labeling techniques are explored to turn this radionuclide into a useful imaging probe. However, efficient separation of Nb-90 from irradiated targets remains in challenge. Ion exchange based separation of Nb-90 from zirconium targets was investigated in systems AG 1 x 8 - HCl/H2O2 and UTEVA-HCl. Nb-95 (t(1/2) = 35.0 d), Zr-95 (t(1/2) = 64.0 d) and (92m) Nb (t(1/2) = 10.15 d) were chosen for studies on distribution coefficients. Separation after AG 1 x 8 anion exchange yields 99% of Nb-90/95. Subsequent use of a solid-phase extraction step on UTEVA resin further decontaminates Nb-90/95 from traces of zirconium with yields 95% of Nb-90/95. A semi-automated separation takes one hour to obtain an overall recovery of Nb-90/95 of 90%. The amount of Zr was reduced by factor of 10(8). The selected separation provides rapid preparation (< 1h) of high purity Nb-90 appropriate for the synthesis of Nb-90-radiopharmaceuticals, relevant for purposes of immuno-PET."

According to the news reporters, the research concluded: "Applying the radioniobium obtained, Nb-90/95-labeling of a monoclonal antibody (rituximab) modified with desferrioxamine achieved labeling yields of > 90% after 1 h incubation at room temperature."

For more information on this research see: Separation of Nb-90 from zirconium target for application in immuno-PET. Radiochimica Acta, 2014;102(5):433-442. Radiochimica Acta can be contacted at: Walter De Gruyter Gmbh, Genthiner Strasse 13, D-10785 Berlin, Germany (see also Radiochemistry).

Our news correspondents report that additional information may be obtained by contacting V. Radchenko, SCKCEN, NTD Silicon Prod, Belgian Nucl Res Center, BE-2400 Mol, Belgium. Additional authors for this research include D.V. Filosofov, O.K. Bochko, N.A. Lebedev, A.V. Rakhimov, H. Hauser, M. Eisenhut, N.V. Aksenov, G.A. Bozhikov, B. Ponsard and F. Roesch.

Keywords for this news article include: Mol, Europe, Belgium, Radiochemistry

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Biotech Week

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters